This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ford, C C Search for Related Content PubMed PubMed Citation Articles by Ford, C C Social Bookmarking                         What's this?

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients

MIND Imaging Center, Albuquerque, NM, USA

K P Johnson

Maryland Center for MS, Baltimore, MD, USA, kjohnson{at}som.umaryland.edu

R P Lisak

Wayne State University, Detroit, MI, USA

H S Panitch

University of Vermont, Burlington, VT, USA

G Shifroni

Teva Pharmaceutical Industries Ltd., Petah Tiqva, Israel

J S Wolinsky

University of Texas Health Science Center at Houston, Houston, TX, USA

The Copaxone® Study Group

A decade of continuous glatiramer acetate (GA) use by relapsing remitting multiple sclerosis (RRMS) patients was evaluated in this ongoing, prospective study, and the neurological status of ‘Withdrawn’ patients was assessed at a 10-year long-term follow-up (LTFU) visit. Modified intention-to-treat (mITT, n=232) patients received 1 GA dose since 1991; ‘Ongoing’ patients (n=108) continued in November 2003. Of 124 patients, 50 Withdrawn patients returned for LTFU. Patients were evaluated every six months (EDSS). Mean GA exposure was 6.99, 10.1 and 4.26 years for mITT, Ongoing, and Withdrawn/LTFU patients, respectively. While on GA, mITT relapse rates declined from 1.18/year prestudy to 1 relapse/5 years; median time to 1 EDSS point increase was 8.8 years; mean EDSS change was 0.739±1.66 points; 58% had stable/improved EDSS scores; and 24, 11 and 3% reached EDSS 4, 6 and 8, respectively. For Ongoing patients, EDSS increased 0.509±1.65; 62% were stable/improved; and 24, 8 and 1% reached EDSS 4, 6 and 8, respectively. For Withdrawn patients at 10-year LTFU, EDSS increased 2.249±1.86; 28% were stable/improved; and 68, 50 and 10% reached EDSS 4, 6 and 8, respectively. While on GA nearly all patients (mean disease duration 15 years) remained ambulatory. At LTFU, Withdrawn patients had greater disability than Ongoing patients.

Key Words: disability • disease modifying therapy • EDSS • glatiramer acetate • immunomodulator • relapse • relapsing-remitting multiple sclerosis

Multiple Sclerosis, Vol. 12, No. 3, 309-320 (2006)
DOI: 10.1191/135248506ms1318oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				V. Skihar, C. Silva, A. Chojnacki, A. Doring, W. B. Stallcup, S. Weiss, and V. W. Yong Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate PNAS, October 20, 2009; 106(42): 17992 - 17997. [Abstract] [Full Text] [PDF]

				W. Carroll Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit Multiple Sclerosis, August 1, 2009; 15(8): 951 - 958. [Abstract] [PDF]

				A. Miller, V. Spada, D. Beerkircher, and R. R. Kreitman Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing--remitting multiple sclerosis Multiple Sclerosis, May 1, 2008; 14(4): 494 - 499. [Abstract] [PDF]

				H.L. Tremlett and J. Oger Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective Multiple Sclerosis, January 1, 2008; 14(1): 94 - 105. [Abstract] [PDF]

				B.R. Sajja, P.A. Narayana, J.S. Wolinsky, C.W. Ahn, and t. P. T. M. G. N/A Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study Multiple Sclerosis, January 1, 2008; 14(1): 73 - 80. [Abstract] [PDF]

				M. Trojano Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis? Neurology, October 9, 2007; 69(15): 1478 - 1479. [Full Text] [PDF]

				M. Rovaris, G. Comi, M. Rocca, P. Valsasina, D. Ladkani, E. Pieri, S. Weiss, G. Shifroni, J. Wolinsky, M. Filippi, et al. Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial Multiple Sclerosis, May 1, 2007; 13(4): 502 - 508. [Abstract] [PDF]

				J. A. Cohen, M. Rovaris, A. D. Goodman, D. Ladkani, D. Wynn, M. Filippi, and for the 9006 Study Group Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS Neurology, March 20, 2007; 68(12): 939 - 944. [Abstract] [Full Text] [PDF]